Jonathan Krinsky, BTIG chief market technician, joins CNBC's Closing Bell to discuss market outlooks.

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired ...

Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that its Digital Health Forum will take place on Monday, November 25, 2024. The event will be hosted by David Larsen, CFA, BTIG Healthcare IT and ...

Plug Power downgraded at BTIG Research, citing need for more product sales to boost margins in the hydrogen market.

BTIG raised the firm’s price target on Syndax (SNDX) to $43 from $35 and keeps a Buy rating on the shares. The firm cites the company having ...

Yet there is another force that could deter Trump from some of his most extreme instincts: the $50 trillion US stock market.

Shares of Core Scientific, Inc. (NASDAQ:CORZ – Get Free Report) have earned an average recommendation of “Buy” from the ...

Fiverr International's (FVRR) stock fell about 4% on Monday after BTIG downgraded the shares to Neutral from Buy, seeing a ...

It has been nearly three years — and four CEOs — since the union labor movement rocked the business and a Starbucks in ...

Finally, BTIG Research raised their price objective on Independence Realty Trust from $18.00 to $21.00 and gave the company a ...

BTIG analyst Gregory Lewis lowered the firm’s price target on Bloom Energy (BE) to $16 from $21 and keeps a Buy rating on the ...